{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T02:03:47Z","timestamp":1773799427286,"version":"3.50.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>OnabotulinumtoxinA is an injectable product that was introduced into medicine in the 1970s and has been the subject of thousands of clinical and nonclinical publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To review the data related to the versatility of onabotulinumtoxinA in medical aesthetics.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>PubMed was searched to identify literature evaluating the effects of onabotulinumtoxinA, with preference given to randomized, placebo-controlled trials and safety meta-analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>OnabotulinumtoxinA is effective and safe across multiple facial indications, racial and ethnic groups, age groups, genders, and facial line severities. Patient-reported outcomes have been prioritized in aesthetic clinical trials and indicate high patient satisfaction and appearance-related psychological outcomes. Integrated safety meta-analysis and immunogenicity analyses have documented acceptable adverse event rates and low immunogenicity of onabotulinumtoxinA.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>OnabotulinumtoxinA is a versatile aesthetic product supported by a strong literature base and positive physician and patient-reported outcomes that reflect a meaningful impact on patient\u2019s quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1097\/dss.0000000000004348","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T23:53:27Z","timestamp":1724889207000},"page":"S12-S17","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Versatility of OnabotulinumtoxinA in Aesthetic Medicine"],"prefix":"10.1097","volume":"50","author":[{"given":"Mitchell F.","family":"Brin","sequence":"first","affiliation":[{"name":"Allergan Aesthetics, An AbbVie Company, Irvine, California;"},{"name":"University of California, Irvine, California; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Maltman","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, An AbbVie Company, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Chapman","sequence":"additional","affiliation":[{"name":"Visage Communications, Mead, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Sangha","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, An AbbVie Company, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"R1-20241006","doi-asserted-by":"crossref","first-page":"e32374","DOI":"10.1097\/MD.0000000000032374","article-title":"Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Scott","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R2-20241006","doi-asserted-by":"crossref","first-page":"e32371","DOI":"10.1097\/MD.0000000000032371","article-title":"Early development history of Botox (onabotulinumtoxinA)","volume":"102","author":"Scott","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R3-20241006","doi-asserted-by":"crossref","first-page":"e32375","DOI":"10.1097\/MD.0000000000032375","article-title":"Treatment of glabellar lines with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Carruthers","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R4-20241006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1524-4725.1992.tb03295.x","article-title":"Treatment of glabellar frown lines with C. botulinum-A exotoxin","volume":"18","author":"Carruthers","year":"1992","journal-title":"J Dermatol Surg Oncol"},{"key":"R5-20241006","doi-asserted-by":"crossref","first-page":"e32373","DOI":"10.1097\/MD.0000000000032373","article-title":"The Pluripotential Evolution and Journey of Botox (onabotulinumtoxinA)","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R10-20241006","doi-asserted-by":"crossref","first-page":"iv14","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20241006","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1067\/mjd.2002.121356","article-title":"A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines","volume":"46","author":"Carruthers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R13-20241006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/01.PRS.0000076504.79727.62","article-title":"Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines","volume":"112","author":"Carruthers","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R14-20241006","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/DSS.0000000000000704","article-title":"Repeated OnabotulinumtoxinA treatment of glabellar lines at rest over three treatment cycles","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"},{"key":"R15-20241006","first-page":"1","article-title":"One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines","volume":"7","author":"Carruthers","year":"2004","journal-title":"J Clin Res"},{"key":"R17-20241006","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with OnabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R18-20241006","first-page":"1544","article-title":"Does increasing the dose of abobotulinumtoxina impact the duration of effectiveness for the treatment of moderate to severe glabellar lines?","volume":"15","author":"Joseph","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R19-20241006","doi-asserted-by":"crossref","first-page":"985","DOI":"10.36849\/JDD.2020.5454","article-title":"IncobotulinumtoxinA demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines","volume":"19","author":"Kerscher","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R20-20241006","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/DSS.0000000000001206","article-title":"Injectable DaxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with OnabotulinumtoxinA and placebo","volume":"43","author":"Carruthers","year":"2017","journal-title":"Dermatol Surg"},{"key":"R21-20241006","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"R22-20241006","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of OnabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"key":"R23-20241006","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00266-012-9932-z","article-title":"Analysis of the patterns of lateral canthal rhytids and reference for botulinum toxin treatment in orientals","volume":"36","author":"Park","year":"2012","journal-title":"Aesthet Plast Surg"},{"key":"R24-20241006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/DSS.0000000000000336","article-title":"Heterogeneity of crow's feet line patterns in clinical trial subjects","volume":"41","author":"Kane","year":"2015","journal-title":"Dermatol Surg"},{"key":"R25-20241006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ijd.14153","article-title":"Characteristics and management of Asian skin","volume":"58","author":"Chan","year":"2019","journal-title":"Int J Dermatol"},{"key":"R27-20241006","first-page":"623","article-title":"Understanding the female Hispanic and Latino American facial aesthetic patient","volume":"18","author":"Fabi","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R28-20241006","first-page":"858","article-title":"Understanding the female African American facial aesthetic patient","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"R29-20241006","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00266-017-0844-9","article-title":"OnabotulinumtoxinA (Botox) in the treatment of crow's feet lines in Japanese subjects","volume":"41","author":"Harii","year":"2017","journal-title":"Aesthet Plast Surg"},{"key":"R30-20241006","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00266-008-9199-6","article-title":"A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects","volume":"32","author":"Harii","year":"2008","journal-title":"Aesthet Plast Surg"},{"key":"R31-20241006","doi-asserted-by":"crossref","first-page":"e2079","DOI":"10.1097\/GOX.0000000000002079","article-title":"Safety and efficacy of OnabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects","volume":"7","author":"Wu","year":"2019","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R32-20241006","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1524-4725.2009.01063.x","article-title":"A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI","volume":"35","author":"Grimes","year":"2009","journal-title":"Dermatol Surg"},{"key":"R33-20241006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/DSS.0000000000002216","article-title":"Efficacy, patient-reported outcomes, and safety for millennial subjects treated with OnabotulinumtoxinA for moderate to severe horizontal forehead lines","volume":"46","author":"Palm","year":"2020","journal-title":"Dermatol Surg"},{"key":"R34-20241006","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/DSS.0000000000000876","article-title":"Facial treatment preferences among aesthetically oriented men","volume":"42","author":"Jagdeo","year":"2016","journal-title":"Dermatol Surg"},{"key":"R35-20241006","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/DSS.0000000000002047","article-title":"Efficacy, patient-reported outcomes, and safety in male subjects treated with OnabotulinumtoxinA for improvement of moderate to severe horizontal forehead lines","volume":"46","author":"Keaney","year":"2020","journal-title":"Dermatol Surg"},{"key":"R36-20241006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1046\/j.1523-1747.2003.12092.x","article-title":"Effect of smoking and sun on the aging skin","volume":"120","author":"Kennedy","year":"2003","journal-title":"J Invest Dermatol"},{"key":"R37-20241006","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1524-4725.2010.01708.x","article-title":"OnabotulinumtoxinA treatment of mild glabellar lines in repose","volume":"36","author":"Carruthers","year":"2010","journal-title":"Dermatol Surg"},{"key":"R38-20241006","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1524-4725.2006.32325.x","article-title":"Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study","volume":"33","author":"Fagien","year":"2007","journal-title":"Dermatol Surg"},{"key":"R39-20241006","doi-asserted-by":"crossref","first-page":"ojz015","DOI":"10.1093\/asjof\/ojz015","article-title":"The psychological impacts of upper facial lines: a qualitative, patient-centered study","volume":"1","author":"Dayan","year":"2019","journal-title":"Aesthet Surg J Open Forum"},{"key":"R40-20241006","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1524-4725.2006.32326.x","article-title":"Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes","volume":"33","author":"Carruthers","year":"2007","journal-title":"Dermatol Surg"},{"key":"R41-20241006","first-page":"27","article-title":"Patient-reported outcomes in Chinese subjects treated with OnabotulinumtoxinA for crow's feet lines","volume":"14","author":"Wu","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"R43-20241006","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/jocd.12166","article-title":"Development and validation of a novel patient-reported treatment satisfaction measure for hyperfunctional facial lines: facial line satisfaction questionnaire","volume":"14","author":"Pompilus","year":"2015","journal-title":"J Cosmet Dermatol"},{"key":"R44-20241006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/jocd.15947","article-title":"Self-perception of natural outcome, appearance, and emotional well-being after OnabotulinumtoxinA treatment for upper facial lines: post hoc analysis across age and gender","volume":"23","author":"Dayan","year":"2024","journal-title":"J Cosmet Dermatol"},{"key":"R45-20241006","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1097\/DSS.0000000000003585","article-title":"High patient satisfaction for up to 6 Months with OnabotulinumtoxinA treatment for upper facial lines","volume":"48","author":"Cohen","year":"2022","journal-title":"Dermatol Surg"},{"key":"R46-20241006","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/toxins15050342","article-title":"Neutralizing antibody formation with OnabotulinumtoxinA (BOTOX\u00ae) treatment from global registration studies across multiple indications: a meta-analysis","volume":"15","author":"Jankovic","year":"2023","journal-title":"Toxins (Basel)"},{"key":"R47-20241006","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdin.2023.07.021","article-title":"Safety and tolerability of onabotulinumtoxinA in the treatment of upper facial lines from global registration studies in 5298 participants: a meta-analysis","volume":"14","author":"Brin","year":"2024","journal-title":"JAAD Int"},{"key":"R48-20241006","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1212\/WNL.0000000000207375","article-title":"Pregnancy outcomes in patients exposed to OnabotulinumtoxinA treatment: a cumulative 29-year safety update","volume":"101","author":"Brin","year":"2023","journal-title":"Neurology"},{"key":"R50-20241006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/toxins15020082","article-title":"Cosmetic treatment using botulinum toxin in the oral and maxillofacial area: a narrative review of esthetic techniques","volume":"15","author":"Hong","year":"2023","journal-title":"Toxins (Basel)"},{"key":"R51-20241006","doi-asserted-by":"crossref","DOI":"10.1097\/PRS.0000000000011472","article-title":"Efficacy and safety of OnabotulinumtoxinA for the treatment of platysma prominence: a randomized phase 2 dose-ranging study","author":"Rohrich","year":"2024","journal-title":"Plast Reconstr Surg"},{"key":"R52-20241006","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/DSS.0000000000004073","article-title":"Efficacy of botulinum toxin in the treatment of cutaneous flushing: a systematic review and meta-analysis","volume":"50","author":"Vincent","year":"2024","journal-title":"Dermatol Surg"},{"key":"R53-20241006","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/toxins12060395","article-title":"Efficacy and safety of botulinum toxin type A on persistent myofascial pain: a randomized clinical trial","volume":"12","author":"De la Torre Canales","year":"2020","journal-title":"Toxins (Basel)"},{"key":"R54-20241006","doi-asserted-by":"crossref","first-page":"e20201035","DOI":"10.1590\/1678-7757-2020-1035","article-title":"Botulinum toxin type A and acupuncture for masticatory myofascial pain: a randomized clinical trial","volume":"29","author":"De la Torre Canales","year":"2021","journal-title":"J Appl Oral Sci"},{"key":"R55-20241006","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/toxins14070441","article-title":"Efficacy of botulinum toxin type-A I in the improvement of mandibular motion and muscle sensibility in myofascial pain TMD subjects: a randomized controlled trial","volume":"14","author":"De la Torre Canales","year":"2022","journal-title":"Toxins (Basel)"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:42:20Z","timestamp":1732707740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":47,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004348","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]}}}